Krystal Biotech vs Praxis Precision Medicines

Krystal Biotech (KRYS), health care, and Praxis Precision Medicines (PRAX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Krystal Biotech is worth $8.8B on the stock market and Praxis Precision Medicines $8.5B: Krystal Biotech is valued at 4% more. Over the past year Krystal Biotech's share price has moved +45.5% and Praxis Precision Medicines's +68.5%.

Key facts

Krystal Biotech market value
$8.8B
Praxis Precision Medicines market value
$8.5B
Krystal Biotech P/E
40.6
Krystal Biotech revenue
$389.1MFY to 2025-12-31
Praxis Precision Medicines revenue
$0FY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Krystal Biotech vs Praxis Precision Medicines: every measure side by side
Measure Krystal Biotech Praxis Precision Medicines
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$8.8Bhigher$8.5Blower
Revenue$389.1Mhigher$0lower
Earnings$204.8Mhigher-$303.3Mlower
Employees295higher168lower
Total assets$1.3Bhigher$937.9Mlower
Valuation
P/E40.6—
P/S22.7—
P/B6.2lower6.8higher
Dividend yield0.00%0.00%
Profitability
Operating margin41.5%—
Balance sheet
Net assets$1.2Bhigher$878.1Mlower
Total liabilities$114.2Mhigher$59.8Mlower
Total debt——
Cash on hand$496.3Mhigher$357.3Mlower
Price change
Today+0.22%higher-1.68%lower
1 year+45.5%lower+68.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Krystal Biotech only (0)

None of the tracked investors.

Praxis Precision Medicines only (2)

Percentages are each holding's share of that investor's reported portfolio. · Who owns PRAX

Further comparisons

Learn

Questions and answers

Which is bigger, Krystal Biotech or Praxis Precision Medicines?

By market value, Krystal Biotech is the larger: $8.8B against $8.5B for Praxis Precision Medicines. By revenue in its latest fiscal year, Krystal Biotech is the larger: $389.1M against $0 for Praxis Precision Medicines.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Krystal Biotech and Praxis Precision Medicines?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Krystal Biotech and 2 hold Praxis Precision Medicines.

Cite this page

Funkfolio, “Krystal Biotech vs Praxis Precision Medicines”, data as of 18 November 2026. https://funkfolio.com/compare/krys-vs-prax

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.